Isomorphic Labs Raises $5 Billion Series C, Largest Life-Sciences VC Round Ever
- Dispatched: Nov 18, 2026 · 18:18 ET (23:18 UTC)
One-sentence summary: Isomorphic Labs, the Alphabet-owned AI drug-discovery company spun out of Google DeepMind, announced on 2026-11-17 07:00 ET / 12:00 UTC a $5 billion Series C co-led by Greenoaks and Sequoia Capital, which the UK BioIndustry Association called the largest venture capital raise in life sciences ever.
Verification status: ✓ Official first-party disclosure (Isomorphic Labs company news release); reported the same day by TechCrunch.
Core Facts & Consensus Delta:
- Financing: $5 billion Series C, announced 2026-11-17 07:00 ET / 12:00 UTC. Co-led by Greenoaks and Sequoia Capital; new investors include Andreessen Horowitz, with continued significant investment from Alphabet and participation from all existing investors (Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund).
- Pace: Six months after a $2.1 billion Series B announced on 2026-05-12; the two rounds total $7.1 billion, taking cumulative funding above $7.7 billion.
- Valuation: The company did not disclose a valuation for the round; Bloomberg had earlier reported it sought funding at about a $50 billion valuation, not yet confirmed.
- Use of proceeds: Scaling its proprietary drug-design engine IsoDDE, its internal and partnered pipeline, and global bioengineering infrastructure, to move AI-designed oncology and immunology candidates into the clinic; the company expects to file its first Investigational New Drug application and begin first-in-human testing before the end of 2026.
- Company background: Spun out of Google DeepMind in 2021; CEO Demis Hassabis, 2024 Nobel laureate in Chemistry for AlphaFold. No candidate has yet entered human trials; all programmes remain preclinical.
Supply-Chain & Market Read-Through:
- AI drug-discovery commercialisation: As the flagship AI-pharma asset in the DeepMind ecosystem, a $5 billion raise sets a funding benchmark for taking AI-designed medicines from computational validation into the clinic; milestone payments and pipeline progress with partners Eli Lilly, Novartis and Johnson & Johnson stand to benefit directly.
- Capital markets: In the same week Anthropic priced its IPO at $83 a share ahead of a 2026-11-19 debut, two large AI-related financings landed together — a sign that primary-market funding for leading AI assets is still expanding, not contracting.
- Compute side: Scaling IsoDDE's simulation models and agents will add demand for high-performance computing and AI infrastructure, though the volume remains modest next to hyperscaler capital expenditure.
Next Catalysts & Watchpoints:
- Before the end of 2026: The first Investigational New Drug filing and first-in-human dosing, testing whether AI-designed molecules can reach the clinic.
- Any later disclosure of the round's valuation, and milestone progress in the Lilly, Novartis and Johnson & Johnson collaborations.
Sources:
- Isomorphic Labs: Isomorphic Labs announces Series C investment round (Published: 2026-11-17 07:00 ET / 12:00 UTC)
- TechCrunch (via TechBytes): Isomorphic Labs raises $5 billion as it looks to take drug candidates (Published: 2026-11-17)
- The Pharma Letter: Isomorphic Labs (2026-11-18; source of the BioIndustry Association "largest life-sciences VC raise" characterisation)
Information only, not investment advice.
Read full 2026-11-18 daily market brief & cross-asset tape → All flash alerts
More flash alerts from 2026-11-18
- US-China Commission Annual Report: PLA Seeking Nvidia's Most Advanced Chips for AI Weapons✓ VERIFIED
- Anthropic Confirms IPO Pricing at $83 a Share, Enlarges Offering to 980 Million Shares for $81.34 Billion✓ VERIFIED
- House Energy and Commerce Committee Writes to Nvidia and Commerce, Seeking Briefings by December 2 on Megaspeed Export Controls✓ VERIFIED
- OpenAI Launches GPT-6.2 Astra and Sol, Cutting Frontier Model Costs by 20%✓ VERIFIED
- ECB to Discuss Doubling Minimum Reserve Requirement to 2% on November 25⚠ UNCONFIRMED
- Ackman Accuses Nvidia Board of Breaching Fiduciary Duties Over Huang Ouster⚠ UNCONFIRMED
- Anthropic Prices IPO at $83 a Share, Valuing Claude Maker at About $1.5 Trillion⚠ UNCONFIRMED
- House Democrats Open Probe Into Whether Lutnick Used Office to Shield Cantor Fitzgerald From Nvidia-Linked Losses⚠ UNCONFIRMED
- AP Calls Alaska Senate Race for Peltola, Locking In a 56-44 Democratic Majority✓ VERIFIED
- Microsoft and Intel Sign Long-Term Azure Deal; Microsoft Becomes First Announced Intel EMIB Packaging Customer✓ VERIFIED
- Fed October Minutes: Almost All Officials Saw Further Hikes as Likely Appropriate, With Unusually Detailed Debate on AI Financing Risks✓ VERIFIED
- Trump Administration Weighs Forcing US Firms to Disclose Use of Chinese AI Models⚠ UNCONFIRMED